Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2011

01-09-2011 | Breast Oncology

To Cut Is to Cure: Can We Really Apply Z11 in Practice?

Authors: Monica Morrow, MD, Armando E. Giuliano, MD

Published in: Annals of Surgical Oncology | Issue 9/2011

Login to get access

Excerpt

Axillary dissection has been a standard part of the local therapy of breast cancer since the popularization of the radical mastectomy by William Halstead in 1894. In 1985, 10-year outcomes from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B04 study were published and showed that in clinically node-negative women, there was no survival advantage for immediate axillary dissection compared to observation and delayed dissection if clinical nodal disease developed.1 In addition, only about half of the patients with nodal metastases (based on the incidence of metastases in the dissection arm) went on to develop clinically evident nodal recurrence. Although this study was extremely influential in our thinking about breast cancer biology, it did not lead to the abandonment of axillary dissection, primarily because nodal status was a selection factor for the use of adjuvant systemic therapy at that time. …
Literature
1.
Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985;312:674–81.PubMedCrossRef
2.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.PubMedCrossRef
3.
van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.PubMedCrossRef
4.
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.PubMedCrossRef
5.
Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426–32.PubMed
6.
Martelli G, Miceli R, Daidone MG, Vetrella G, Cerrotta AM, Piromalli D, et al. Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Ann Surg Oncol. 2011;18:125–33.PubMedCrossRef
7.
Greco M, Agresti R, Cascinelli N, Casalini P, Giovanazzi R, Maucione A, et al. Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg. 2000;232:1–7.PubMedCrossRef
8.
Grills IS, Kestin LL, Goldstein N, Mitchell C, Martinez A, Ingold J, et al. Risk factors for regional nodal failure after breast-conserving therapy: regional nodal irradiation reduces rate of axillary failure in patients with four or more positive lymph nodes. Int J Radiat Oncol Biol Phys. 2003;56:658–70.PubMedCrossRef
9.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.PubMedCrossRef
10.
Crabb SJ, Cheang MC, Leung S, Immonen T, Nielsen TO, Huntsman DD, et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer. 2008;8:249–56.PubMedCrossRef
11.
Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol. 2009;16:2705–10.PubMedCrossRef
12.
Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009;27:2466–73.PubMedCrossRef
13.
Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial. J Clin Oncol. 2007;25:3259–65.PubMedCrossRef
14.
Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27:2946–53.PubMedCrossRef
Metadata
Title
To Cut Is to Cure: Can We Really Apply Z11 in Practice?
Authors
Monica Morrow, MD
Armando E. Giuliano, MD
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 9/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1857-2

Other articles of this Issue 9/2011

Annals of Surgical Oncology 9/2011 Go to the issue

Breast Oncology

The Choice for Breast Cancer Surgery: Can Women Accurately Predict Postoperative Quality of Life and Disease-Related Stigma?

Gastrointestinal Oncology

A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer

Breast Oncology

Toward Optimization of Imaging System and Lymphatic Tracer for Near-Infrared Fluorescent Sentinel Lymph Node Mapping in Breast Cancer

Gynecologic Oncology

Robotics Versus Laparoscopic Radical Hysterectomy with Lymphadenectomy in Patients with Early Cervical Cancer: A Multicenter Study

Colorectal Cancer

Prognostic Significance of Preoperative Bowel Obstruction in Stage III Colorectal Cancer

Melanomas

How Do We Know When a Lymph Node Dissection is Adequate?